Matches in SemOpenAlex for { <https://semopenalex.org/work/W51158438> ?p ?o ?g. }
- W51158438 endingPage "1433" @default.
- W51158438 startingPage "1427" @default.
- W51158438 abstract "No AccessJournal of Urology1 Nov 1993Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic Carcinoma Eric J. Kuhn, Richard A. Kurnot, Isabell A. Sesterhenn, Esther H. Chang, and Judd W. Moul Eric J. KuhnEric J. Kuhn More articles by this author , Richard A. KurnotRichard A. Kurnot More articles by this author , Isabell A. SesterhennIsabell A. Sesterhenn More articles by this author , Esther H. ChangEsther H. Chang More articles by this author , and Judd W. MoulJudd W. Moul More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)35799-3AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The objective of this study was to determine the expression of the c-erbB-2 oncoprotein via immunohistochemistry of archival clinically localized human prostate cancers and to compare these results to known clinical prognostic factors. In addition, positive staining cases were subjected to differential polymerase chain reaction to assess for c-erbB-2 gene amplification. Immunohistochemical staining with a polyclonal antibody (pAb 1) was performed on archival radical prostatectomy specimens. To standardize the staining, positive and negative control material was generated using c-erbB-2 transfected NIH3T3 cells grown on agar plugs, formalin fixed, paraffin embedded and processed on glass slides for immunohistochemistry. Definite positive membranous staining was detected in 18 of 53 neoplastic cases (34%). In addition, 9 cases of benign prostatic hyperplasia were stained without evidence of c-erbB-2 expression detected. Either focal or diffuse membranous staining was identified in 6 of 27 (22%) well, 8 of 20 (40%) moderately and 4 of 6 (66%) poorly differentiated tumors (p = 0.03, chi-square test for trend). Positive staining occurred in 6 of 18 patients (33%) with pathological stage B and 12 of 33 (36%) with pathological stage C disease. At a mean of 36 months, complete followup was available for 16 of the 18 positive cases and 30 of the 35 negative cases. For stage B 1 of 6 positive (16.7%) versus 1 of 12 negative (8%) staining cases showed progression (p = 1.0). For stage C 7 of 12 positive (58.3%) versus 9 of 21 negative (42.9%) cases showed progression (p = 0.48). Deoxyribonucleic acid was extracted from the exact same archival paraffin blocks for the c-erbB-2 protein positive cases and subjected to differential polymerase chain reaction analysis, which revealed no c-erbB-2 gene amplification. This study demonstrates that approximately a third of all clinically localized prostate cancers express the c-erbB-2 oncoprotein via immunohistochemistry using pAb-1 on archival material, c-erbB-2 oncoprotein expression does not appear to be a prognostic marker for prostate cancer although our results are preliminary and, although oncoprotein expression was detected, no positive case demonstrated deoxyribonucleic acid amplification. © 1993 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited BySchäfer W, Funke P, Kunde D, Rausch U, Wennemuth G and Stützer H (2018) Intensity of Androgen and Epidermal Growth Factor Receptor Immunoreactivity in Samples of Radical Prostatectomy as Prognostic Indicator: Correlation With Clinical Data of Long-Term ObservationsJournal of Urology, VOL. 176, NO. 2, (532-537), Online publication date: 1-Aug-2006.KREJCI K, MARKIEWICZ M and KWON E (2018) Immunotherapy for Urological MalignanciesJournal of Urology, VOL. 171, NO. 2, (870-876), Online publication date: 1-Feb-2004. Volume 150Issue 5 Part 1November 1993Page: 1427-1433 Advertisement Copyright & Permissions© 1993 by The American Urological Association Education and Research, Inc.Keywordsoncogenesoncogene productsDNA, neoplasmprostatic neoplasmsMetricsAuthor Information Eric J. Kuhn More articles by this author Richard A. Kurnot More articles by this author Isabell A. Sesterhenn More articles by this author Esther H. Chang More articles by this author Judd W. Moul More articles by this author Expand All Advertisement Loading ..." @default.
- W51158438 created "2016-06-24" @default.
- W51158438 creator A5007664700 @default.
- W51158438 creator A5014371717 @default.
- W51158438 creator A5025046669 @default.
- W51158438 creator A5033253417 @default.
- W51158438 creator A5039264253 @default.
- W51158438 date "1993-11-01" @default.
- W51158438 modified "2023-10-17" @default.
- W51158438 title "Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic Carcinoma" @default.
- W51158438 cites W1772131958 @default.
- W51158438 cites W1807228574 @default.
- W51158438 cites W1957044910 @default.
- W51158438 cites W1965372133 @default.
- W51158438 cites W1967819851 @default.
- W51158438 cites W1971178416 @default.
- W51158438 cites W1974260910 @default.
- W51158438 cites W2001627828 @default.
- W51158438 cites W2005529016 @default.
- W51158438 cites W2006115709 @default.
- W51158438 cites W2007256480 @default.
- W51158438 cites W2015394676 @default.
- W51158438 cites W2020088393 @default.
- W51158438 cites W2037722366 @default.
- W51158438 cites W2053579461 @default.
- W51158438 cites W2054430764 @default.
- W51158438 cites W2057563358 @default.
- W51158438 cites W2059031630 @default.
- W51158438 cites W2060531515 @default.
- W51158438 cites W2065493522 @default.
- W51158438 cites W2089382354 @default.
- W51158438 cites W2089487481 @default.
- W51158438 cites W2095156669 @default.
- W51158438 cites W2096428903 @default.
- W51158438 cites W2136779985 @default.
- W51158438 cites W2139397808 @default.
- W51158438 cites W2141393790 @default.
- W51158438 cites W2276418696 @default.
- W51158438 cites W2410021467 @default.
- W51158438 cites W2426196179 @default.
- W51158438 doi "https://doi.org/10.1016/s0022-5347(17)35799-3" @default.
- W51158438 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8105108" @default.
- W51158438 hasPublicationYear "1993" @default.
- W51158438 type Work @default.
- W51158438 sameAs 51158438 @default.
- W51158438 citedByCount "150" @default.
- W51158438 countsByYear W511584382012 @default.
- W51158438 countsByYear W511584382014 @default.
- W51158438 countsByYear W511584382015 @default.
- W51158438 crossrefType "journal-article" @default.
- W51158438 hasAuthorship W51158438A5007664700 @default.
- W51158438 hasAuthorship W51158438A5014371717 @default.
- W51158438 hasAuthorship W51158438A5025046669 @default.
- W51158438 hasAuthorship W51158438A5033253417 @default.
- W51158438 hasAuthorship W51158438A5039264253 @default.
- W51158438 hasConcept C121608353 @default.
- W51158438 hasConcept C126322002 @default.
- W51158438 hasConcept C142724271 @default.
- W51158438 hasConcept C159654299 @default.
- W51158438 hasConcept C203014093 @default.
- W51158438 hasConcept C204232928 @default.
- W51158438 hasConcept C2776235491 @default.
- W51158438 hasConcept C2777546739 @default.
- W51158438 hasConcept C2777562237 @default.
- W51158438 hasConcept C2779466945 @default.
- W51158438 hasConcept C3018264335 @default.
- W51158438 hasConcept C71924100 @default.
- W51158438 hasConcept C74864618 @default.
- W51158438 hasConcept C956191 @default.
- W51158438 hasConceptScore W51158438C121608353 @default.
- W51158438 hasConceptScore W51158438C126322002 @default.
- W51158438 hasConceptScore W51158438C142724271 @default.
- W51158438 hasConceptScore W51158438C159654299 @default.
- W51158438 hasConceptScore W51158438C203014093 @default.
- W51158438 hasConceptScore W51158438C204232928 @default.
- W51158438 hasConceptScore W51158438C2776235491 @default.
- W51158438 hasConceptScore W51158438C2777546739 @default.
- W51158438 hasConceptScore W51158438C2777562237 @default.
- W51158438 hasConceptScore W51158438C2779466945 @default.
- W51158438 hasConceptScore W51158438C3018264335 @default.
- W51158438 hasConceptScore W51158438C71924100 @default.
- W51158438 hasConceptScore W51158438C74864618 @default.
- W51158438 hasConceptScore W51158438C956191 @default.
- W51158438 hasIssue "5 Part 1" @default.
- W51158438 hasLocation W511584381 @default.
- W51158438 hasLocation W511584382 @default.
- W51158438 hasOpenAccess W51158438 @default.
- W51158438 hasPrimaryLocation W511584381 @default.
- W51158438 hasRelatedWork W1997473564 @default.
- W51158438 hasRelatedWork W1997615822 @default.
- W51158438 hasRelatedWork W2021528614 @default.
- W51158438 hasRelatedWork W2023820302 @default.
- W51158438 hasRelatedWork W2090571842 @default.
- W51158438 hasRelatedWork W2351810720 @default.
- W51158438 hasRelatedWork W2363746292 @default.
- W51158438 hasRelatedWork W2400167340 @default.
- W51158438 hasRelatedWork W2417159962 @default.
- W51158438 hasRelatedWork W3170907609 @default.